Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Incyte  (Stock symbol: INCY )

Route 141 & Henry Clay Road
Wilmington, Deleware 19880
Website Company Summary Management Team

Outside board: (May no longer be on the board) Barry M Ariko (Extricity Software) Julian C Baker (Baker-Tisch Investments);  Paul Brooke (PMS Holdings Partners);  Frederick B Craves (Management Consultant) Richard De Schutter (DuPont Pharma);  Jon S Saxe (Hoffman-La Roche)
Former outside board: Barry Bloom (Pfizer EVP R&D);  Jeff Collison (Schroeder Ventures)

Business description: Incyte, Inc., has the largest commercial portfolio of issued United States patents covering human, full-length genes and the proteins they encode. Incyte is leveraging its leading intellectual property and genomic information position to be a leader in discovering and developing therapeutic small molecules, secreted proteins and antibodies. In addition, Incyte has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease.
Customers include: JohnsonAndJohnson;  Glaxo;  Monsanto;  Phizer;  Upjohn
Partners include: GenentechJohnsonAndJohnsonPfizer;  Boston University;  Hoescht AG;  Layton Pharm;  Novo Nordisk;  Upjohn;  Zeneca

Rounds: 4
Capital raised: 9.7M
Ownership: Public  
Stock Symbol: INCY
Angels/other VCs: David Blech
Corporate investors: Genentech;  Ciba Geigy

Last Tweets


Last Mentions

Sector: Biotech
Year Founded: 1991
Headcount: 401-500 as of Nov 2002
Rounds: 4
Capital Raised: 9.7M
Ownership: Public  
Stock Symbol: INCY